Dr. Herman Waldmann
Scientific Advisory Board
Served as Department Head and Professor Emeritus of Pathology at the Oxford Medical School and Clinical Director of Oxford’s Therapeutic Antibody Centre. Dr. Waldmann gained his BA, MD and PhD at Cambridge, where he was also Professor of Therapeutic Immunology. He is a key figure in the field of immune system regulation. A past winner of the prestigious Starzl Prize in Surgery and Immunology from the Starzl Transplantation Institute at the University of Pittsburg. Dr. Waldmann received a SCRIP Lifetime Achievement Award, one of the most prestigious awards in the biotechnology industry.
Throughout his three decades at Oxford, Dr. Waldmann’s focus has been on regulation of immune response and his current interest is in reprogramming the immune system to accept histoincompatible stem cell-derived transplants. His pioneering work in the use of therapeutic monoclonal antibodies to induce immune tolerance was translated into Lemtrada, a Multiple Sclerosis treatment developed by Genzyme (Sanofi) and approved by the FDA after achieving significantly reduced relapse rates of the disease. Dr. Waldmann has served on multiple advisory boards including the UK Medical Research Council, a UK government agency, the Wellcome Trust, a global charitable organization, and Cancer Research UK, all of which provide major funding of UK biomedical research.
Dr. Steven Burakoff
Scientific Advisory Board
Dr. Steven Burakoff, Director of the Tisch Cancer Institute at Mount Sinai Medical Center and Professor of Cancer Medicine and Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai Center. Dr. Burakoff, who served as a Research Fellow at Harvard Medical School under Professor Benacerraf, a Nobel Laureate in Physiology and Medicine for his work in immunology, went on to become a Professor at Harvard Medical School. At New York University School of Medicine he served as Director of both the Skirball Institute of Biomolecular Medicine and the NYU Cancer Institute and Kaplan Comprehensive Cancer Center before joining Mount Sinai Medical Center.
Dr. Burakoff’s ongoing research focus is on T cell activation, mismatched bone marrow transplantation and translational cancer research. He was Chair of Pediatric Oncology and served on the Executive Committee of the Board of Trustees at the Dana Farber Cancer Institute, Chaired the Advisory Committee on Immunology and Immunotherapy of the American Cancer Society and in 2009 received a Lifetime Achievement Award from the American Association of Immunologists. Dr. Burakoff has served as a consultant to Novartis, Bristol Myers Squibb and Hoffman Laroche and was on the Board of Directors of Genzyme Corporation when it was acquired by Sanofi-Aventis in 2011 for over $20 billion.
Dr. Robert Negrin
Scientific Advisory Board
Director of the Bone and Marrow Transplantation Division and Professor of Medicine at Stanford University. Dr. Negrin received his medical degree at Harvard Medical School and training in Internal Medicine and Hematology at Stanford University. He is the Program Leader of the Immunology and Immunotherapy of Cancer Program at the Stanford University Cancer Center. He is currently an Associate Editor of Blood (the weekly journal of the American Society of Hematology) and has served on the editorial boards of the Journal of Clinical Oncology and Biology of Blood and Marrow Transplantation.
Having taught at Stanford for 25 years, Dr. Negrin has spent the past decade focusing on the use of T cells in immunotherapy. He has served as the President of the American Society of Bone and Marrow Transplantation and the International Society of Cellular Therapy. He is an elected member of the Association of American Physicians. Dr. Negrin has earned research awards from the National Institutes of Health, the Leukemia Society of America and the Jose Carerras Leukemia Foundation and was a Doris Duke Distinguished Clinical Scientist Awardee.
Dr. Hermann Einsele
Scientific Advisory Board
Professor of Internal Medicine and Director of the Department of Internal Medicine of the Julius Maximilian University, Würzburg, Germany. Dr. Einsele trained in Germany and the UK, and was a Research Fellow in the Department of Hematology, Oncology, Rheumatology, and Immunology at the University of Tübingen, Germany. A former visiting professor at both the Fred Hutchinson Cancer Research Center in Seattle, WA and at the City of Hope Hospital in Duarte, CA, Professor Einsele is a member of the American Society of Hematology (ASH) as well as the European Hematology Association (EHA).
Dr. Einsele is the Chairman of the German Study Group on Multiple Myeloma and serves on the Board of Directors of both the German Society of Blood and Marrow Stem Cell Transplantation and the German Lymphoma Group. He is part of the working group for Infectious Disease, Chronic Leukemia and Immunobiology at the European Group for Blood and Marrow Transplantation (EBMT). A past recipient of the van Bekkum Award, the highest annual European award for research in the field of stem cell transplantation, he is an Honorary Fellow of the Royal College of Pathologists (London), and was the 2012 Nobel Lecturer on Stem Cell Biology/Transplantation at the Nobel Forum, Karolinska Institute (Sweden).
Dr. Michael Farber
Strategic Patent Advisor
Dr. Farber is a Partner with Ditthavong & Steiner P.C. and member of their Intellectual Property Practice involving patents, trademarks, and copyrights. He specializes in biotechnology patent prosecution including genetic engineering, immunochemistry, cellular immunology, monoclonal antibodies and genomics. Over the past four decades, he has served as IP counsel at Catalyst Law Group, Oppenheimer Wolff & Donnelly, Merchant & Gould and Sheldon & Mak.
Dr. Farber started his education at the California Institute of Technology where he earned his B.S. in Biology. He then attended Harvard University where he was awarded a National Institutes of Health Fellowship and then went on to earn his Ph.D. in Biochemistry & Molecular Biology. He earned his J.D. Magna Cum Laude from Southwestern University School of Law in Los Angeles where he received an American Jurisprudence Award. He is the co-author of “The Scope of Patent Protection for Physiologically Important Proteins and Peptides,” Biopharm, 1990.
Chief Executive Officer, Chief Financial Officer and Director
A Canadian businessman and a founding member of Cell Source. Since Cell Source Israel's inception, Mr. Shimrat served as a Director, Chief Financial Officer and, in October 2013, he was appointed Chief Executive Officer. Previously, Mr. Shimrat served as an Executive Vice President and Division Head at First International Bank of Israel (FIBI), where he founded and led the strategic planning function, including planning, strategy, strategic marketing & branding and project management oversight functions. He led a successful rebranding and repositioning of the bank and during his tenure the bank's ROE was doubled.
Previously, Mr. Shimrat worked as an international management consultant, chiefly at McKinsey & Co., and he led successful major profit improvement programs for top tier financial institutions including Barclays in England and the Commonwealth Bank of Australia. He began his management consulting career at Bain & Company, where he participated in the development of a new global retail strategy for Citibank. He holds an MBA with Distinction from the Ivey Business School of the University of Western Ontario in Canada.